FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3158897801> ?p ?o ?g. }

• W3158897801 endingPage "20" @default.
• W3158897801 startingPage "1" @default.
• W3158897801 abstract "The activities of the ephrin family in breast cancer (BrCa) are complex. Family A receptors (EPHA) and ligands (EFNA) can act as oncogenes or tumor suppressors and are implicated in chemoresistance. Here, we examined the expression pattern and prognostic value of the EPHA/EFNA family in patients with breast cancer, including patients with different subtypes or different chemotherapy cohorts. In the UALCAN database, the mRNA expression of EPHA1, EPHA10, EFNA1, EFNA3, and EFNA4 was significantly higher, whereas that of EPHA2, EPHA4, EPHA5, and EFNA5 was significantly lower in breast cancer tissues than in paracancerous tissues. The transcriptional levels of EPHA/EFNA family members were correlated with intrinsic subclasses of breast cancer. The relationship between EPHA/EFNA and the clinicopathological parameters of BrCa was analyzed using bc-GenExMiner V4.5. EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 were upregulated in estrogen receptor- (ER-) and progesterone receptor- (PR-) negative tumors, whereas EPHA3, EPHA6, and EFNA1 were upregulated in ER- and PR-positive tumors. EPHA1, EPHA2, EFNA3, and EFNA4 mRNA expression was significantly higher in human epidermal growth factor receptor 2- (HER2-) positive tumors than in HER2-negative tumors. Triple-negative status was positively correlated with EPHA1, EPHA2, EPHA4, EPHA7, EFNA3, EFNA4, and EFNA5 and negatively correlated with EPHA3 and EPHA10 mRNA expression. Genetic alterations of EPHA/EFNA in breast cancer varied from 1.1% to 10% for individual genes, as determined by the cBioPortal database. The Kaplan–Meier plotter indicated that high EphA7 mRNA expression was associated with poor overall survival (OS) and recurrence-free survival (RFS), especially in the HER2 and luminal A subtypes. EFNA4 was predicted to have poor OS and RFS in breast cancers, especially in luminal B, basal-like subtype, and patients treated with adjuvant chemotherapy. High EPHA3 expression was significantly associated with better OS and RFS, especially in the luminal A subtype, but with poor RFS in BrCa patients receiving chemotherapy. Our findings systematically elucidate the expression pattern and prognostic value of the EPHA/EFNA family in BrCa, which might provide potential prognostic factors and novel targets in BrCa patients, including those with different subtypes or treated with chemotherapy." @default.
• W3158897801 created "2021-05-10" @default.
• W3158897801 creator A5000801878 @default.
• W3158897801 creator A5007100425 @default.
• W3158897801 creator A5015885395 @default.
• W3158897801 creator A5047448171 @default.
• W3158897801 creator A5056101043 @default.
• W3158897801 creator A5089587198 @default.
• W3158897801 date "2021-04-22" @default.
• W3158897801 modified "2023-10-17" @default.
• W3158897801 title "Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy" @default.
• W3158897801 cites W1967720639 @default.
• W3158897801 cites W1976310806 @default.
• W3158897801 cites W1976867481 @default.
• W3158897801 cites W1990148464 @default.
• W3158897801 cites W1992187858 @default.
• W3158897801 cites W1995535201 @default.
• W3158897801 cites W1997670728 @default.
• W3158897801 cites W2000000810 @default.
• W3158897801 cites W2004485044 @default.
• W3158897801 cites W2008259383 @default.
• W3158897801 cites W2011907603 @default.
• W3158897801 cites W2014858105 @default.
• W3158897801 cites W2022671765 @default.
• W3158897801 cites W2029299821 @default.
• W3158897801 cites W2030498911 @default.
• W3158897801 cites W2044858733 @default.
• W3158897801 cites W2045216597 @default.
• W3158897801 cites W2047523756 @default.
• W3158897801 cites W2055154486 @default.
• W3158897801 cites W2064781878 @default.
• W3158897801 cites W2082338146 @default.
• W3158897801 cites W2083227014 @default.
• W3158897801 cites W2085934079 @default.
• W3158897801 cites W2088852482 @default.
• W3158897801 cites W2089398124 @default.
• W3158897801 cites W2094161067 @default.
• W3158897801 cites W2095333719 @default.
• W3158897801 cites W2114625470 @default.
• W3158897801 cites W2114843025 @default.
• W3158897801 cites W2118258530 @default.
• W3158897801 cites W2131876608 @default.
• W3158897801 cites W2132893003 @default.
• W3158897801 cites W2139429540 @default.
• W3158897801 cites W2149441684 @default.
• W3158897801 cites W2158320248 @default.
• W3158897801 cites W2158485828 @default.
• W3158897801 cites W2168148385 @default.
• W3158897801 cites W2242433351 @default.
• W3158897801 cites W2259934843 @default.
• W3158897801 cites W2736730167 @default.
• W3158897801 cites W2749631812 @default.
• W3158897801 cites W2767132912 @default.
• W3158897801 cites W2791923588 @default.
• W3158897801 cites W2795353688 @default.
• W3158897801 cites W2899977607 @default.
• W3158897801 cites W2966360269 @default.
• W3158897801 cites W3010167508 @default.
• W3158897801 cites W3081041850 @default.
• W3158897801 cites W4229680502 @default.
• W3158897801 doi "https://doi.org/10.1155/2021/5575704" @default.
• W3158897801 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8087473" @default.
• W3158897801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33977106" @default.
• W3158897801 hasPublicationYear "2021" @default.
• W3158897801 type Work @default.
• W3158897801 sameAs 3158897801 @default.
• W3158897801 citedByCount "5" @default.
• W3158897801 countsByYear W31588978012022 @default.
• W3158897801 countsByYear W31588978012023 @default.
• W3158897801 crossrefType "journal-article" @default.
• W3158897801 hasAuthorship W3158897801A5000801878 @default.
• W3158897801 hasAuthorship W3158897801A5007100425 @default.
• W3158897801 hasAuthorship W3158897801A5015885395 @default.
• W3158897801 hasAuthorship W3158897801A5047448171 @default.
• W3158897801 hasAuthorship W3158897801A5056101043 @default.
• W3158897801 hasAuthorship W3158897801A5089587198 @default.
• W3158897801 hasBestOaLocation W31588978011 @default.
• W3158897801 hasConcept C101544691 @default.
• W3158897801 hasConcept C104317684 @default.
• W3158897801 hasConcept C121608353 @default.
• W3158897801 hasConcept C126322002 @default.
• W3158897801 hasConcept C127561419 @default.
• W3158897801 hasConcept C143998085 @default.
• W3158897801 hasConcept C150582083 @default.
• W3158897801 hasConcept C170493617 @default.
• W3158897801 hasConcept C502942594 @default.
• W3158897801 hasConcept C530470458 @default.
• W3158897801 hasConcept C54355233 @default.
• W3158897801 hasConcept C71924100 @default.
• W3158897801 hasConcept C84606932 @default.
• W3158897801 hasConcept C86803240 @default.
• W3158897801 hasConceptScore W3158897801C101544691 @default.
• W3158897801 hasConceptScore W3158897801C104317684 @default.
• W3158897801 hasConceptScore W3158897801C121608353 @default.
• W3158897801 hasConceptScore W3158897801C126322002 @default.
• W3158897801 hasConceptScore W3158897801C127561419 @default.
• W3158897801 hasConceptScore W3158897801C143998085 @default.
• W3158897801 hasConceptScore W3158897801C150582083 @default.

• next